ELISA: 1/20000approx. 1/40000. Western Blot: 1/500approx. 1/1000. Immunohistochemistry: 1/50approx. 1/200. Immunofluorescence: 1/50approx. 1/200. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Target
JIP3 (MAPK8IP3)
(Mitogen-Activated Protein Kinase 8 Interacting Protein 3 (MAPK8IP3))
Andere Bezeichnung
JIP-3
Hintergrund
C-Jun NH2-terminal kinases (JNKs) are distant members of the MAP kinase family. JNK1 is activated by dual phosphorylation at a Thr-Pro-Tyr motif in response to ultraviolet (UV) light, and it functions to phosphorylate c-Jun at amino terminal serine regulatory sites Ser 63 and Ser 73, resulting in transcriptional activation. Two additional JNK family members, JNK2 and JNK3, have been identified. JIP-1 (for JNK interacting protein-1) has been identified as a cytoplasmic inhibitor of JNK that retains JNK in the cytoplasm, thereby inhibiting JNK-regulated gene expression. Evidence suggests that JNK1 and JNK2 bind to JIP-1 with greater affinity than to ATF-2 and c-Jun, which are targets of the JNK signaling pathway. JIP-1 contains an amino terminal JNK binding domain and a carboxy terminal SH3 domain. ATF-2 and c-Jun also contain the JNK binding domain and are thought to compete with JIP-1 for JNK binding. Multiple splice variants of JIP-1, including JIP-1b, JIP-1c (also designated islet-brain 1 or IB-1), JIP-2a, JIP-2b and JIP-3, have been identified in brain.Synonyms: C-jun-amino-terminal kinase-interacting protein 3, JIP3, JNK MAP kinase scaffold protein 3, JNK-interacting protein 3, MAPK8IP3, Mitogen-activated protein kinase 8-interacting protein 3